Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro

Leukemia

Volumn 10, Issue 12, 1996, Pages 1919-1924

  Schroder J K ^a   Kirch, C ^a   Flasshove, M ^a   Kalweit, H ^a   Seidelmann, M ^a   Hilger, R ^a   Seeber, S ^a   Schutte J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cytidine deaminase; Cytosine arabinoside; Drug resistance; Gene therapy; Myeloid leukemia

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; CYTARABINE; CYTIDINE DEAMINASE; DNA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG RESISTANCE; ENZYME ACTIVITY; FIBROBLAST CULTURE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 12644266362     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 1987; 166: 210-218.
2. Sorrentino BP, Brandt SJ, Bodine D, Gottesmann M, Pastan I, Cline A, Nienhuis AW. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257 99-103.
3. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retroviral-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and vivo. Cancer Res 1995; 55: 2608-2614.
4. Estey EH, Kantarjian H, Keating MJ. Therapy for acute myeloid leukemia. In: R Hoffman, EJ Benz Jr, SS Shattil, B Furie, HJ Cohen, LE Silberstein (eds). Hematology - Basic Principles and Practice, 2nd edn. Churchill Livingstone: New York, 1995, pp 1014-1028.
5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura CA, Moore JO, McIntyre OR, Frei E III, for the Cancer and Leukemia Croup B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
6. Cassileth PA, Lynch E, Mines JD, Oken MM, Mazza JL, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
7. Weiner KXB, Weiner RS, Maley F, Maley GF. Primary structure of human deoxycytidylate deaminase and overexpression of its functional protein in Escherichia coli. J Biol Chem 1993; 268: 12983-12989.
8. Kühn K, Bertling WM, Emmrich F. Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as marker of monocyte/macrophage differentiation. Biochem Biophys Res Commun 1993; 190: 1-7.
9. Bertling W, Beier F, Reichenberger E. Determination of 5′ ends of specific mRNAs by DNA ligase-dependent amplification. PCR Meth Appl 1993; 3: 95-99.
10. Laliberte J, Momparler RL. Human cytidine deaminase; purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 1994; 5: 5401-5407.
11. Capizzi RL, White JC, Powell BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991; 28: (Suppl. 4): 54-69.
12. Chirgwin J, Przybyla A, MacDonald R, Rutter W. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-5299.
13. Arcari P, Martinelli R, Salvatore F. A complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res 1984; 12: 9179-9185.
14. Lobel L, Goff S. Reverse transcription of retroviral genomes: mutation in the terminal repeat sequences. J Virol 1985; 53: 447-455.
15. Schütte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. Jun-B inhibits and c-fos stimulates the transforming and transactivating activities of c-jun. Cell 1989; 59: 987-997.
16. Steuart CD, Burke PJ. Cytidine deaminase and the development of resistance to arabinoside cytosine. Nature New Biol 1971; 233: 109-110.
17. Momparler RL, Laliberte J. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. Leukemia Res 1990; 14: 751-754.
18. Hurley MC, Pallella TD, Fox IH. Human placental deoxyadenosine and deoxyguanosine phosphorylating activity. J Biol Chem 1983; 258: 15021-15027.
19. Hurley MC, Fox IH. Measurement of nucleoside kinases in crude tissue extracts. Biochem Med 1983; 30: 89-100.
20. Nygaard P, Sundström C. Low cytidine deaminase levels in human hematopoietic cell lines. Leukemia Res 1987; 11: 681-685.
21. Abe I, Saito S, Hori K, Suzuki M, Sato H. Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 1982; 42: 2846-2851.
22. Ellims PH, Kao AY, Chabner BA. Kinetic behaviour and allosteric regulation of human deoxycytidylate deaminase derived from leukemic cells. Mol Cell Biochem 1983; 57: 185-190.
23. Fridland A, Verhoef V. Mechanism for ara-CTP catabolsim in human leukemic cells and effects of deaminase inhibitors on this process. Semin Oncol 1987; 14 (Suppl. 1): 262-268.
24. Jamieson GP, Finch LR, Snook M, Wiley JS. Degradation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res 1987; 47: 3130-3135.
25. Jamieson GP, Snook MB, Bradley TR, Bertoncello I, Wiley JS. Transport and metabolism of 1-β-D-arabinofuranosylcytosine in human ovarian adenocarcinoma. Cancer Res 1989; 49: 309-313.
26. Ho DHW. Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973; 33: 2816-2820.
27. Tattersall MHN, Ganeshaguru K, Hoffbrand AV. Mechanism of resistance of human acute leukemia cells to cytosine arabinoside. Br J Haematol 1974; 27: 39-46.
28. Colly LP, Peters WG, Richel D, Arentsen-Honders MW, Starrenburg CWJ, Willemze R. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myeloid leukemia. Semin Oncol 1987; 14 (Suppl. 1): 257-261.
29. Yusa K, Ohuhara T, Tsukabara S, Tsuoro T. Human immunodeficiency virus type I induces 1-β-D-arabinofuranosylcytosine resistance in human H9 cell line. J Biol Chem 1992; 267: 16848-16850.
30. Yang JL, Cheng EH, Capizzi RL, Cheng YC, Kute T. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. J Clin Invest 1985; 75: 141-146.
31. Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983; 1: 763-771.
32. Müller WEG, Zahn RK. Metabolism of 1-β-D-arabinofuranosyl-uracil in mouse L5178Y cells. Cancer Res 1979; 39: 1102-1107.
33. Kessel D, Shurin S. Transport of two non-metabolized nucleosides, deoxycytidine and cytosine arabinoside, in a subline of the L1210 murine leukemia. Biochim Biophys Acta 1968; 163: 179-187.
34. Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrozosek C, Early AP, Preisler H. Relationship between plasma ara-C and intracellular ara CTP pools under conditions of continuous infusion and high dose ara-C treatment. Med Pediatr Oncol 1982; 1 (Suppl): 33-43.
35. Chottiner EC, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH, Mitchell BS. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 1991; 88: 1531-1535.
36. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992; 52: 2389-2393.
37. Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, Seeber S, Schütte J. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994; 8: 780-785.
38. Grant S, Turner A, Nelms P, Yanovich S. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-β-D-arabinofuranosylcytosine. Leukemia 1995; 9: 808-814.
39. Li M, Hantzopoulos PA, Banerjee D, Zhao SC, Schweitzer BI, Gilboa E, Bertino JR. Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther 1992; 3: 381-390.